drugset

drugset / Trial / NCT00209846

A Study of Gaboxadol in Primary Insomnia

NCT00209846 ↗

Phase 3 Completed 320 enrolled H. Lundbeck A/S

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the safety and tolerability of gaboxadol in primary insomnia.

Timeline

Start: 2004-06
Primary completion: —
Completion: 2006-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	gaboxadol	Small molecule	—	—

Indications